-
Class 1.1 new drug dp-vpa of Enhua pharmaceutical was approved for clinical application
Time of Update: 2015-03-24
The new drug dp-vpa (API and tablet) of Jiangsu Enhua Pharmaceutical (sz002262) was declared in February 2014 and approved for clinical application on March 16, 2015 The evaluation time of the drug is
-
Jiangsu Weikeli medicine class 1.1 new drug Viagra approved clinical
Time of Update: 2015-03-23
The class 1.1 new drug Viagra (tablet) of Jiangsu Weikeli Pharmaceutical Technology Co., Ltd was declared in May 2014, and was approved for clinical application on March 10, 2015 The review time is 10
-
BMS and zaiding pharmaceutical sign the brivanib license agreement
Time of Update: 2015-03-23
Bristol Myers Squibb (NYSE Code: BMY) and China's leading innovative pharmaceutical company Zai lab today jointly announced that they have signed an agreement that zaidin will have the exclusive right
-
CDE drug review weekly report (2015.3.16-3.22)
Time of Update: 2015-03-23
1 Among the 26 drugs approved to enter the approval process this week, 14 are chemical drugs, 4 are traditional Chinese medicine, 5 are biological products for treatment, 2 are biological products for
-
Haizheng pharmaceutical's heavyweight new drug "ambrano" was not approved as expected
Time of Update: 2015-03-23
Haizheng pharmaceutical's heavyweight new drug "ambenox" (recombinant human tumor necrosis factor II receptor antibody fusion protein for injection) has not yet received the final approval, but the co
-
Class 1 antiepileptic drug dp-vpa of Enhua pharmaceutical has completed technical approval
Time of Update: 2015-03-20
According to the information on the website of CFDA on March 20, the clinical application status of dp-vpa API and tablet for class 1 new drug of Enhua Pharmaceutical (002262 SZ) is displayed as "unde
-
"Tianjin University - North China Pharmaceutical crystallization Engineering Laboratory"
Time of Update: 2015-03-20
On March 12, Professor Yin Qiuxiang, director of the national industrial crystallization engineering technology research center of Tianjin University, Professor Gong Junbo, deputy director, Professor
-
Lilly will work with Cinda bio pharmaceutical to develop anticancer drugs
Time of Update: 2015-03-20
Lilly has reached a cooperation agreement with China Cinda biopharmaceutical (Suzhou) Co., Ltd to jointly develop at least three kinds of anti-cancer drugs, which will be one of the most extensive coo
-
Class 1.1 new drug of Zhejiang medicine, nanofloxacin malate, entered the site for inspection this month
Time of Update: 2015-03-19
According to information on CFDA's website, Zhejiang Pharmaceutical (600216 SH) will enter the drug registration and production site for inspection this month According to the drug review process, the
-
CDE drug review weekly report (March 1-March 15, 2015)
Time of Update: 2015-03-18
Among the 70 drugs that entered the approval process in the first half of March, there were 51 chemicals, 10 traditional Chinese medicines and 9 biological products for treatment There are a lot of cl
-
Local innovative pharmaceutical research and development company released two phase clinical trial data of hepatitis C new drug ASC08
Time of Update: 2015-03-18
Dr Wu Jinzi, President and CEO of Hangzhou Song Li Biotechnology (Hangzhou) Co., Ltd delivered a speech China's indigenous innovation and drug research and development company today announced its dire
-
CDE drug registration backlog further increased
Time of Update: 2015-03-18
On March 13, the drug review center of the State Food and Drug Administration (hereinafter referred to as the "drug review center") officially released the 2014 annual drug review report on its websit
-
Ibn-1, a new diabetes drug in Changshan pharmaceutical industry, is expected to be approved in the near future
Time of Update: 2015-03-17
According to the website information of CFDA on March 16, the clinical application status of ibonatide injection and API, a new class 1 drug of Changshan Pharmaceutical Co., Ltd., is "under approval",
-
Zhongyuan Xiehe stem cell new drug has not been approved clinically
Time of Update: 2015-03-17
Zhongyuan Xiehe announced last night that the application for registration of heavy-duty stem cell drug umbilical cord mesenchymal stem cell anti fibrosis injection was not approved Last week, it was
-
Lenalidomide and dasatinib, the heavyweight new drugs of Shuanglu pharmaceutical industry, may be approved within this year
Time of Update: 2015-03-17
Since the beginning of the year, the stock price trend of Shuanglu Pharmaceutical Co., Ltd has been "bright in the sky" with a record high Before that, Shuanglu pharmaceutical's share price had been t
-
In 2014, the backlog of pending drugs in China rose by one third
Time of Update: 2015-03-16
By the end of 2014, there were more than 18500 drugs waiting to be approved in China, a third higher than last year On Friday (March 13), officials at the drug review center expressed concern that app
-
Tazarotene betamethasone cream, a new drug of psoriasis Class 1.5 of Huabang pharmaceutical, will be on the market soon
Time of Update: 2015-03-16
According to the website of the State Food and Drug Administration (CFDA), the state of 1.5 skin disease drug tazarotene betamethasone cream of Huabang pharmaceutical was changed to "under approval",
-
Leading edge biological long-term treatment of AIDS original new drug ibove Taiwang takes the lead in the market
Time of Update: 2015-03-16
There are 35.3 million people infected with HIV, 2.3 million new infections and 1.6 million people died of AIDS This shocking set of figures tells us that AIDS has become the biggest threat to human h
-
Lvgu pharmaceutical and Shanghai Pharmaceutical Research Institute sign technology transfer contracts for two new anticancer drug projects
Time of Update: 2015-03-14
In the first action plan recently launched by the Chinese Academy of Sciences, Shanghai Pharmaceutical Institute took the lead in preparing for the establishment of the pharmaceutical innovation resea
-
Chinese researchers found that graphene can cure cavities
Time of Update: 2015-03-13
Dental diseases are caused by the growth of some oral bacteria, which is the most common health problem in the world Scientists have found that a graphene oxide material can effectively eliminate thes
